Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies  

作　　者：Zhiyang Ling Chunyan Yi Xiaoyu Sun Zhuo Yang Bing Sun 

机构地区：[1]State Key Laboratory of Cell Biology,Shanghai Institute of Biochemistry and Cell Biology,Center for Excellence in Molecular Cell Science,Chinese Academy of Sciences,Shanghai 200031,China [2]University of Chinese Academy of Sciences,Beijing 100049,China [3]School of Life Science and Technology,ShanghaiTech University,Shanghai 201210,China

出　　处：《Science China(Life Sciences)》2023年第4期658-678,共21页中国科学（生命科学英文版）

基　　金：supported by grants from the Ministry of Science and Technology of China(2018YFA0507402);the Key International Partnership Program of the Chinese Academy of Sciences(153D31KYSB20180055);the National Natural Science Foundation of China(32270991,32100123,32100751)。

摘　　要：Antibody therapeutics and vaccines for coronavirus disease 2019(COVID-19)have been approved in many countries,with most being developed based on the original strain of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).SARS-CoV-2 has an exceptional ability to mutate under the pressure of host immunity,especially the immune-dominant spike protein of the virus,which is the target of both antibody drugs and vaccines.Given the continuous evolution of the virus and the identification of critical mutation sites,the World Health Organization(WHO)has named 5 variants of concern(VOCs):4 are previously circulating VOCs,and 1 is currently circulating(Omicron).Due to multiple mutations in the spike protein,the recently emerged Omicron and descendent lineages have been shown to have the strongest ability to evade the neutralizing antibody(NAb)effects of current antibody drugs and vaccines.The development and characterization of broadly neutralizing antibodies(bNAbs)will provide broad strategies for the control of the sophisticated virus SARS-CoV-2.In this review,we describe how the virus evolves to escape NAbs and the potential neutralization mechanisms that associated with bNAbs.We also summarize progress in the development of bNAbs against SARS-CoV-2,human coronaviruses(CoVs)and other emerging pathogens and highlight their scientific and clinical significance.

关 键 词：antibody therapy broad neutralizing antibody human coronaviruses SARS-CoV-2 

分 类 号：R392-33[医药卫生—免疫学]